Evidence map›Paper›PMID 35042101›Full record

ArticleDrug and alcohol dependence2022

Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs.

Sarah Gutkind, Laura E Starbird, Sean M Murphy, Paul A Teixeira, Lauren K Gooden, Tim Matheson, Daniel J Feaster, Mamta K Jain, Carmen L Masson, David C Perlman and 3 more

Open access · greenAbstract read
In one paragraph

Article in Drug and alcohol dependence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Sarah GutkindDepartment of Population Health Sciences, Weill Cornell Medical College, 425 E 61st St, New York, NY 10065, USA. Electronic address: sg3787@cumc.columbia.edu.
Laura E StarbirdColumbia University School of Nursing, 560 West 168th St, New York, NY 10032, USA. Electronic address: starbird@nursing.upenn.edu.
Sean M MurphyDepartment of Population Health Sciences, Weill Cornell Medical College, 425 E 61st St, New York, NY 10065, USA. Electronic address: smm2010@med.cornell.edu.
Paul A TeixeiraDepartment of Population Health Sciences, Weill Cornell Medical College, 425 E 61st St, New York, NY 10065, USA. Electronic address: pault212@gmail.com.
Lauren K GoodenDepartment of Sociomedical Sciences, Mailman School of Public Health, Columbia University, 722 W 168th St, New York, NY 10032, USA. Electronic address: lkg2129@columbia.edu.
Tim MathesonSan Francisco Department of Health, 101 Grove St, San Francisco, CA 94102, USA. Electronic address: tim.matheson@sfdph.org.
Daniel J FeasterDepartment of Epidemiology and Public Health, University of Miami School of Medicine, 1120 NW 14th St Miami, FL 33136, USA. Electronic address: DFeaster@biostat.med.miami.edu.
Mamta K JainDepartment of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA. Electronic address: Mamta.Jain@UTSouthwestern.edu.
Carmen L MassonDepartment of Psychiatry and Behavioral Sciences, University of California San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA. Electronic address: Carmen.Masson@ucsf.edu.
David C PerlmanIcahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA. Electronic address: David.Perlman@mountsinai.org.
Carlos Del RioDepartment of Global Health, Rollins School of Public Health at Emory University, 1518 Clifton Rd NE, Atlanta, GA 30322, USA. Electronic address: cdelrio@emory.edu.
Lisa R MetschDepartment of Sociomedical Sciences, Mailman School of Public Health, Columbia University, 722 W 168th St, New York, NY 10032, USA. Electronic address: lm2892@columbia.edu.
Bruce R SchackmanDepartment of Population Health Sciences, Weill Cornell Medical College, 425 E 61st St, New York, NY 10065, USA. Electronic address: brs2006@med.cornell.edu.
Cornell University · USColumbia University · USEmory University · USIcahn School of Medicine at Mount Sinai · USSan Francisco Department of Public Health · USSouthwestern Medical Center · USUniversity of California, San Francisco · USUniversity of Miami · US

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Project-004UG1DA020024 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI Steven J Shoptaw, MADHUKAR H. TRIVEDI · 2015 to 2026
$71.6M
FLORIDA NODE OF THE DRUG ABUSE CLINICAL TRIALS NETWORKU10DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI METSCH, LISA R, SZAPOCZNIK, JOSE · 2000 to 2015
$56.9M
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials NetworkUG1DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel J Feaster, Viviana Elizabeth Horigian · 2015 to 2026
$50.6M
Transdisciplinary Theoretical Svnthesis and Development CoreP30DA011041 · NIDA · NEW YORK UNIVERSITY · PI Holly Hagan · 1998 to 2026
$38.9M
University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Savita Pahwa · 2007 to 2026
$33.8M
Western States Node of the National Drug Abuse Treatment Clinical Trials NetworkU10DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCARTY, DENNIS, SORENSEN, JAMES L · 2002 to 2015
$25.2M
Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6M
Concept ProjectU10DA020024 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI TRIVEDI, MADHUKAR H. · 2005 to 2015
$22.6M
Institute for Integration of Medicine & Science: A Partnership to Improve HealthUM1TR004538 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ROBERT A CLARK, Kenneth M Hargreaves · 2023 to 2026
$22.3M
NCATS NIH HHS UM1 TR004538NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI073961NIDA NIH HHS HHSN271201400028CNIDA NIH HHS K01 DA051348NIDA NIH HHS P30 DA011041NIDA NIH HHS P30 DA040500NIDA NIH HHS T32 DA031099NIDA NIH HHS T32 DA037801NIDA NIH HHS U10 DA013720NIDA NIH HHS U10 DA015815NIDA NIH HHS U10 DA020024NIDA NIH HHS UG1 DA013034NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA013720NIDA NIH HHS UG1 DA015815NIDA NIH HHS UG1 DA015831NIDA NIH HHS UG1 DA020024NINR NIH HHS L30 NR018771NINR NIH HHS T32 NR014205
6 · The paper itself

Abstract

backgroundUsing data from a randomized trial, we evaluated the cost of HCV care facilitation that supports moving along the continuum of care for HIV/HCV co-infected individuals with substance use disorder.

methodsParticipants were HIV patients residing in the community, initially recruited from eight US hospital sites. They received HCV care facilitation (n = 51) or treatment as usual (n = 62) for up to six months. We used micro-costing methods to evaluate costs from the healthcare sector and patient perspectives in 2017 USD. We conducted sensitivity analyses varying care facilitator caseloads and examined offsetting savings using participant self-reported healthcare utilization.

resultsThe average site start-up cost was $6320 (site range: $4320-$7000), primarily consisting of training. The mean weekly cost per participant was $20 (site range: $4-$30) for care facilitation visits and contacts, $360 (site range: $130- $700) for supervision and client outreach, and $70 (site range: $20-$180) for overhead. In sensitivity analyses applying a weekly caseload of 10 participants per care facilitator (versus 1-6 observed in the trial), the total mean weekly care facilitation cost from the healthcare sector perspective decreased to $110. Weekly participant time and travel costs averaged $7. There were no significant differences in other healthcare service costs between participants in the intervention and control arms.

conclusionWeekly HCV care facilitation costs were approximately $450 per participant, but approximately $110 at a real-world setting maximum caseload of 10 participants per week. No healthcare cost offsets were identified during the trial period, although future savings might result from successful HCV treatment.

Indexed as

CoinfectionHepatitis CHIV InfectionsCost-Benefit AnalysisHealth Care CostsHepacivirusHumansCare facilitationCostHepatitis CHIVSubstance use disorder

Identifiers

PMID35042101
PMCPMC9238179
OpenAlexW4206147611

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.